Novo Nordisk: The hypoglycemic drug Frehemgo is expected to be launched in Europe in the fourth quarter of 2026 and marketed throughout the European Union in early 2027.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.